A 2025 research paper finds that obese individuals with low choline levels face increased Alzheimer’s disease risk due to inflammation and neuronal damage, highlighting dietary interventions. Re...
The Phase 3 failure of semaglutide in Alzheimer’s disease highlights challenges in repurposing GLP-1 agonists, urging a shift towards biomarker-driven and personalized approaches in neurodegener...
